Orrick Advised Catalyst Biosciences on $60 Million Sale of Complement Portfolio
| May.24.2022
Orrick advised South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc.
Client Results
Orrick Advises Stripes on Investment in Hello Heart
| May.03.2022
Orrick advised Stripes on its investment in digital therapeutics company Hello Heart’s $70 million Series D funding round.
Orrick Advises Twist Bioscience on Upsized Public Offering of Common Stock
| March.09.2022
Orrick advises Twist Bioscience on upsized public offering of common stock.
Orrick Advises Dompé on 2022 R&D Collaboration with and Series A Investment in Engitix
| January.21.2022
We advised Dompé farmaceutici S.P.A (Dompé) on its multi-year, multi-program strategic research and development collaboration with Engitix Ltd.
Orrick Advises Avilex Pharma on Strategic Partnership with Simcere Pharmaceutical Group
| December.17.2021
The agreement grants Simcere an exclusive regional license to develop and commercialize AVLX-144, Avilex’s Phase 2-ready dimeric PSD-95 inhibitor.
Orrick Advises Opentrons Labworks on $200 Million Series C Round
| September.24.2021
Opentrons will use this fundraising round to further invest in its automated lab platform globally.
Federal Circuit Reverses $1.2 Billion Judgment Against Client Gilead Sciences
| August.26.2021
The U.S. Court of Appeals for the Federal Circuit today overturned a $1.2+ billion patent infringement judgment against Gilead’s Kite Pharma unit.
Orrick Advises Cerba HealthCare in Acquisition of Lifebrain
| July.26.2021
Attilio Mazzilli led a team that assisted Cerba HealthCare, a leader in outpatient diagnostics, in the acquisition of the entire stake of Lifebrain.
Orrick Advises HCW Biologics on $56 Million IPO
| July.20.2021
Orrick is advising HCW Biologics on its $56 million initial public offering of 7 million shares of common stock.
Orrick Advises Rafael Pharmaceuticals on Merger with Rafael Holdings
| June.21.2021
Orrick is advising Rafael Pharmaceuticals, a clinical-stage oncology company, on its proposed merger with Rafael Holdings.
Insights
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q2 2022
| April.26.2022
A Conversation on Leveraging Spinouts to Preserve and Create Value During Financing Rounds, M&A and IPO Planning
The DOJ’s Focus on Clinical Trial Enforcement: An Ounce of Prevention Is Better Than an Enforcement Action Cure
by Thora Johnson, Gargi Talukder, David Rhinesmith and Matthew Reeder | April.26.2022
The U.S. DOJ Civil Division’s Consumer Protection Branch (CPB) first-ever “Recent Highlights” report leads with CPB’s work on consumer health and ...
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q1 2022
| February.16.2022
A Conversation on the Future of Longevity, Cell Regeneration and Senescence
Year-End Roundup for Health Data Privacy: What Life Sciences and Healthcare Companies Need to Know for 2022
by Thora Johnson, Shannon Yavorsky, David Curtis, Melanie Phillips and Alyssa Wolfington | January.27.2022
Six noteworthy trends that life sciences and healthcare companies should continue to keep an eye on in 2022.
Orrick State Attorneys General Newsletter – December 2021
by Rob McKenna, Brian T. Moran, Andrew Cook and Erica Sechrist | December.17.2021
Orrick's State Attorneys General team examines recent actions around the United States.
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q4 2021
| October.19.2021
VC Investment Surges in European Life Science
Health Tech Companies Should Prepare for New Information Blocking Rules to Ensure Compliance
by Thora Johnson, Heather Sussman and Ryan McKenney | September.27.2021
We analyze new rules prohibiting information blocking rules for health tech companies and outline steps they can take to ensure compliance.
Playtime is Over for Apps Collecting Health‐Related Data – FTC Announces Intent to Enforce Health Breach Rule
by Thora Johnson, Emily S. Tabatabai, Hannah Levin and Melanie Phillips | September.23.2021
The U.S. Federal Trade Commission issued a policy statement providing clarity on the scope of its 2009 Health Breach Notification Rule.
Cybersecurity and Privacy Threats and Risks for Life Sciences and Healthcare Companies
by Thora Johnson, Adele Harrison and Hannah Levin | July.22.2021
Attacks on the life sciences and healthcare sectors increased significantly in the last year.
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q3 2021
| July.21.2021
A Conversation on Spinouts – Unlocking Market Value and Creating Business Opportunities
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q2 2021
| April.20.2021
Record-breaking Markets and a Candid Conversation on University Spinouts
Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q1 2021
| February.01.2021
We review full-year 2020 data in depth to identify and summarize the key trends that shaped venture investment across the sector.
Using M&A Insurance on Tech Deals (Issue 3): Fintech, edtech and healthtech/medtech
by Peter M. Lamb, David M. Ruff, Hari Raman, Daniel Lopez and Zac Padgett | January.21.2021
We dig deeper into key underwriting topics for fintech, edtech and healthtech/medtech deals.
Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q3 2020
| October.22.2020
Venture Surges and the Rise of SPACs
In this edition, the traditional update on broader venture market financing data is included.
In this edition, the traditional update on broader venture market financing data is included.
Investments in Germany under COVID 19 – Turning a Crisis into Opportunities
by Dr. Oliver Duys LL.M. (UNSW Sydney) and Abhijit Narayan | August.17.2020
This article provides an overview about the recent investment trends in Germany in view of the COVID-19 pandemic.
Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q2 2020
| August.10.2020
Companies & Investors Navigate the Pandemic Era
In this new series, we explore trends in venture investing across the life sciences sector.
In this new series, we explore trends in venture investing across the life sciences sector.
News
Orrick Continues Growth of Life Sciences & Tech Team
| February.22.2022
Welcome to Tony Chan who joins the firm as a partner focused on advising companies and investors in the life sciences and tech sectors.
Orrick Expands Antitrust Team with Two DC Hires
| January.03.2022
Eileen Cole and Craig Falls join the firm as partners in our Antitrust and Competition practice.
Orrick Adds Life Sciences Adviser and Former Prosecutor to White Collar Team
| October.11.2021
Orrick welcomes Franklin Monsour, a former federal prosecutor and experienced white collar and regulatory adviser to the life sciences sector.
LMG Life Sciences Names Orrick its 2021 Finance & Corporate Firm to Watch
| September.27.2021
LMG recognizes the individuals and companies behind the most innovative and challenging life sciences work of the past year.
Orrick Expands Cyber & Privacy Team with a Health Tech Focus
| July.07.2021
Orrick announced today that Thora Johnson has joined our Cyber, Privacy & Data Innovation practice as a partner in Washington, DC.
Veteran Advisor Mike O’Donnell Joins Orrick’s Life Sciences Team
| July.01.2021
Welcome Mike O’Donnell, a leading advisor to the Life Sciences sector, who has joined the firm as a partner in Silicon Valley. He is the 9th addition ...